114 related articles for article (PubMed ID: 17443134)
1. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects.
Jin Y; Wang YH; Miao J; Li L; Kovacs RJ; Marunde R; Hamman MA; Philips S; Hilligoss J; Hall SD
Clin Pharmacol Ther; 2007 Nov; 82(5):579-85. PubMed ID: 17443134
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.
Kim KA; Park PW; Lee OJ; Choi SH; Min BH; Shin KH; Chun BG; Shin JG; Park JY
Clin Pharmacol Ther; 2006 Dec; 80(6):646-56. PubMed ID: 17178265
[TBL] [Abstract][Full Text] [Related]
3. Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.
Kim KA; Park PW; Park JY
Chirality; 2009 May; 21(5):485-91. PubMed ID: 18752284
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.
Suh JW; Koo BK; Zhang SY; Park KW; Cho JY; Jang IJ; Lee DS; Sohn DW; Lee MM; Kim HS
CMAJ; 2006 Jun; 174(12):1715-22. PubMed ID: 16754899
[TBL] [Abstract][Full Text] [Related]
5. Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
Fuhr U; Müller-Peltzer H; Kern R; Lopez-Rojas P; Jünemann M; Harder S; Staib AH
Eur J Clin Pharmacol; 2002 Apr; 58(1):45-53. PubMed ID: 11956673
[TBL] [Abstract][Full Text] [Related]
6. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.
Kim KA; Park PW; Lee OJ; Kang DK; Park JY
J Clin Pharmacol; 2007 Jan; 47(1):87-93. PubMed ID: 17192506
[TBL] [Abstract][Full Text] [Related]
7. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.
Wong M; Balleine RL; Collins M; Liddle C; Clarke CL; Gurney H
Clin Pharmacol Ther; 2004 Jun; 75(6):529-38. PubMed ID: 15179407
[TBL] [Abstract][Full Text] [Related]
9. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
[TBL] [Abstract][Full Text] [Related]
10. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
[TBL] [Abstract][Full Text] [Related]
11. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction.
Ling S; Jamali F
Basic Clin Pharmacol Toxicol; 2009 Jul; 105(1):24-9. PubMed ID: 19371259
[TBL] [Abstract][Full Text] [Related]
12. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
[TBL] [Abstract][Full Text] [Related]
13. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
14. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
[TBL] [Abstract][Full Text] [Related]
16. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
17. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
18. No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy.
Lieb W; Bolbrinker J; Döring A; Hense HW; Erdmann J; Schunkert H; Kreutz R
Clin Sci (Lond); 2006 Dec; 111(6):365-72. PubMed ID: 16822233
[TBL] [Abstract][Full Text] [Related]
19. Genotyping cytochrome P450 3A5 using the Light Cycler.
Fredericks S; Moreton M; MacPhee IA; Mohamed M; Marlowe S; Jorga A; Johnston A; Carter ND; Holt DW
Ann Clin Biochem; 2005 Sep; 42(Pt 5):376-81. PubMed ID: 16168193
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]